(ङ) उपर्युक्त गैर अधिकतम कीमत (खुदरा मूल्य) केवल उपर्युक्त निर्माता/विपणन के लिए लागू है जैसा कि उन्होंने औषध (मूल्य नियंत्रण) आदेश, 2013 के तहत अनुबद्ध मूल्य निर्धारण/संशोधन के लिए फॉर्म I पर जमा किया गया था और सरकार द्वारा निर्धारित सभी लागू वैधानिक आवश्यकताओं की पूर्ति के अधीन प्रासंगिक विधियों/नियमों के अन्तर्गत जैसा कि केन्द्रीय/राज्य लाइसेंसिंग ऑथोरिटी के सक्षम प्राधिकारी द्वारा मैन्यूफैक्चरिंग लाइसेंस मंजूरी के तहत संबंधित विनिर्मित निर्माता/विपणन कम्पनियां जो अनुपालन करती हैं।

(च) विनिर्माता या विपणन कम्पनी, उपरोक्त विनिर्मितियों और विनिर्दिष्ट शर्तों का पालन नहीं करती है तो वे आवश्यक वस्तुएँ अधिनियम, 1955 के साथ पठित डीपीसीओ, 2013 के प्रावधानों के अधीन ब्याज सहित अधिप्रभारित राशि को जमा करने के लिए उत्तरदायी होंगे।

(छ) इस आदेश में उपरोक्त तालिका के कॉलम (3) और (5) में तत्स्थानी प्रविष्टियों में निर्दिष्ट विनिर्माण और विपणन कंपनियों की स्ट्रेंथ और नाम के साथ, उपरोक्त तालिका के कॉलम (2) में निर्दिष्ट ऐसे फॉर्मूलेशन के खुदरा मूल्य के निर्धारण के परिणामस्वरूप, कॉलम (2), (3) और (5) में तत्स्थानी प्रविष्टियों में यथा निर्दिष्ट उस विनिर्माण और विपणन कंपनियों के लिए निर्दिष्ट स्ट्रेंथ के साथ फॉर्मूलेशन के खुदरा मूल्य को निर्धारित करने वाले कोई मूल्य आदेश यदि इस अधिसूचना से पहले जारी किए गए हो, तो उसे इसका स्थान लिया माना जाएगा।

[पीएन/272/140/2025/एफ/फा. सं. 8(140)/2025/डीपी/एनपीपीए-डिवीजन-II]

महावीर सैनी, उप निदेशक

MINISTRY OF CHEMICALS AND FERTILIZERS

(Department of Pharmaceuticals)

(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)

ORDER

New Delhi, the 28th November, 2025

S.O. 5476(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

TABLE

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Bisoprolol Fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Intas Pharmaceuticals Ltd.	10.49
2	Bisoprolol Fumarate & Telmisartan Tablets	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Windlas Biotech Ltd./ M/s Intas Pharmaceuticals Ltd.	12.09
3	Ceftriaxone & Sulbactam for Injection	Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone 250 mg	1 vial	M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd.	65.30

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
		Sulbactam Sodium IP Eq. to Sulbactam 125 mg			
4	Ceftriaxone & Sulbactam for Injection	Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone 500 mg Sulbactam Sodium IP Eq. to Sulbactam 250 mg	1 vial	M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd.	104.32
5	Ceftriaxone, Disodium Edetate & Sulbactam powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP (Sterile) Eq. to Ceftriaxone 1000 mg Disodium Edetate IP 37 mg Sulbactam Sodium IP (Sterile) Eq. to Sulbactam 500 mg	1 vial	M/s Gufic Biosciences Ltd./ M/s Criticare Division LLP	567.13
6	Ceftriaxone, Disodium Edetate & Sulbactam powder for solution for infusion	Each vial contains: Ceftriaxone Sodium IP (Sterile) Eq. to Ceftriaxone 2000 mg Disodium Edetate IP 74 mg Sulbactam Sodium IP (Sterile) Eq. to Sulbactam 1000 mg	1 vial	M/s Gufic Biosciences Ltd./ M/s Criticare Division LLP	1140.26
7	Levocetirizine Dihydrochloride & Montelukast Sodium Syrup	Each 5 ml of Syrup contains: Levocetirizine Dihydrochloride IP 2.5 mg Montelukast Sodium IP Eq. to Montelukast 4 mg	1 ml	M/s East African (I) Overseas / M/s SRK Puremed LLP	1.48
8	Telmisartan & Amlodipine Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 80 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg	1 Tablet	M/s Unison Pharmaceuticals Pvt. Ltd.	16.00
9	Telmisartan & Hydrochlorothiazide Tablets	Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Hydrochlorothiazide IP 12.5 mg	1 Tablet	M/s Swiss Garnier Life Sciences / M/s SRK Puremed LLP	7.52
10	Cefixime & Ofloxacin Oral Suspension	Each 5ml of reconstituted suspension contains: Cefixime trihydrate IP eq to Cefixime anhydrous 50mg Ofloxacin IP 50mg	1 ml	M/s Prosperity Drugs Private Limited/ M/s Cachet Pharmaceuticals Pvt. Ltd.	1.74
11	Teneligliptin, Dapagliflozin, Metformin (Sustained Release) Tablets	Each film-coated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20 mg Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg Metformin Hydrochloride IP 500 mg (As Sustained Release)	1 Tablet	M/s Synokem Lifesciences Pvt. Ltd / M/s Glenmark Pharmaceuticals Ltd.	12.15

Notes:

(a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification

as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

[PN/272/140/2025/F/F. No. 8(140)/2025/D.P./NPPA-Div.-II]

MAHAVEER SAINI, Dy. Director

Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.